GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MOA Life Plus Co Ltd (XKRX:142760) » Definitions » EV-to-EBITDA

MOA Life Plus Co (XKRX:142760) EV-to-EBITDA : -21.65 (As of Jun. 20, 2024)


View and export this data going back to 2014. Start your Free Trial

What is MOA Life Plus Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MOA Life Plus Co's enterprise value is ₩71,961.32 Mil. MOA Life Plus Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-3,323.93 Mil. Therefore, MOA Life Plus Co's EV-to-EBITDA for today is -21.65.

The historical rank and industry rank for MOA Life Plus Co's EV-to-EBITDA or its related term are showing as below:

XKRX:142760' s EV-to-EBITDA Range Over the Past 10 Years
Min: -135.39   Med: -21.13   Max: 39.88
Current: -21.65

During the past 10 years, the highest EV-to-EBITDA of MOA Life Plus Co was 39.88. The lowest was -135.39. And the median was -21.13.

XKRX:142760's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 8.44 vs XKRX:142760: -21.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-20), MOA Life Plus Co's stock price is ₩2090.00. MOA Life Plus Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩163.736. Therefore, MOA Life Plus Co's PE Ratio for today is 12.76.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


MOA Life Plus Co EV-to-EBITDA Historical Data

The historical data trend for MOA Life Plus Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MOA Life Plus Co EV-to-EBITDA Chart

MOA Life Plus Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.97 -13.95 -11.82 -41.41 32.21

MOA Life Plus Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -125.14 36.72 30.56 32.21 -24.06

Competitive Comparison of MOA Life Plus Co's EV-to-EBITDA

For the Biotechnology subindustry, MOA Life Plus Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MOA Life Plus Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MOA Life Plus Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MOA Life Plus Co's EV-to-EBITDA falls into.



MOA Life Plus Co EV-to-EBITDA Calculation

MOA Life Plus Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=71961.323/-3323.929
=-21.65

MOA Life Plus Co's current Enterprise Value is ₩71,961.32 Mil.
MOA Life Plus Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,323.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MOA Life Plus Co  (XKRX:142760) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MOA Life Plus Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2090.00/163.736
=12.76

MOA Life Plus Co's share price for today is ₩2090.00.
MOA Life Plus Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩163.736.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


MOA Life Plus Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MOA Life Plus Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


MOA Life Plus Co (XKRX:142760) Business Description

Traded in Other Exchanges
N/A
Address
767, Sinsu-Ro, 7th Floor, Suji-gu, Gyeonggi-do, Yongin-Si, KOR, 305-500
BL Corp, formerly Bioleaders Corp engages in the biomedicine and biomaterial business in South Korea. It develops cervical intraepithelial dysplasia treatment which is in phase 3 clinical-stage; cervical cancer treatment which is in phase 2b clinical stage; and non-clinical vaccine adjuvant and treatment for muscular dystrophy.

MOA Life Plus Co (XKRX:142760) Headlines

No Headlines